Efficacy and safety of secukinumab for the treatment of severe ABCA12 deficiency‐related ichthyosis in a child
Summary Background Patients with severe autosomal recessive congenital ichthyosis (ARCI) show a T helper 17/interleukin 17 (Th17/IL17) skewing in their skin and serum, resembling the inflammatory profile of psoriatic patients. Secukinumab, an IL‐17A inhibitor, has shown clinical efficacy in patients...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-06-01
|
| Series: | Skin Health and Disease |
| Online Access: | https://doi.org/10.1002/ski2.25 |